Abstract Aim According to the European Association of Urology (EUA) guidelines, patients with muscle invasive bladder cancer (MIBC) have better overall survival outcome if they receive definitive treatment within 90 days from point of referral. Our objective was to assess the average timeline of these patients from their 2 week wait (2WW) referral to definitive treatment. Method This was a retrospective study in all patients diagnosed with MIBC from 1st January 2018 to 31st December 2019 at Furness General Hospital (UHMBT). Treatment delay was defined as delay in more than 90 days from initial referral to definitive treatment (radical cystectomy /radical radiotherapy with or without adjuvant chemotherapy). Results 47 patients met the inclusion criteria. Patients had imaging within 27 days, with 32 patients (68%) having a computed tomography (CT) scan and 15 patients (32%) having magnetic resonance imaging (MRI). The duration from referral point to transurethral resection of bladder tumour (TURBT) was 40 days. Multidisciplinary team (MDT) discussion took place within 12 days post-surgery. On average, the journey from date of referral to MDT was 52 days. From MDT discussion to the first tertiary centre appointment took another 27 days making it a total of approximately 79 average days for the patient to have a definitive treatment plan. Conclusions 12 patients (26%) exceeded the 90-day mark from duration between referral to having treatment. This is mainly due to TURBT being used as the ‘stop the clock’ treatment. The trust has, thus, created a departmental standard operating procedure (SOP) with the aim of minimising this duration.